JAB-21822 is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JAB-21822’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JAB-21000 is under development for the treatment of colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer and other solid tumors. The drug candidate acts by targeting KRAS G12C. It is developed based on allosteric inhibitor discovery platform. It is administered orally as a tablet.
Jacobio Pharmaceuticals Group overview
Jacobio Pharmaceuticals Group (Jacobio Pharma) discovers and develops monotherapies to treat cancer. The company is investigating JAB-3068 program for the treatment of solid tumors, esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC); JAB-3312 drug against pancreatic cancer and KRAS mutation in colorectal cancer, osimertinib progressed and KRAS G12C mutation in NSCLC. It is also evaluating JAB-8263 drug to treat solid tumors, myelofibrosis and acute myeloid leukemia (AML). Jacobio Pharma works in partnership with entrepreneurs, biotechnology and pharmaceutical companies. The company operates with research and development centers in Beijing and Shanghai, China and Boston, the US. Jacobio Pharma is headquartered in Beijing, China.
For a complete picture of JAB-21822’s drug-specific PTSR and LoA scores, buy the report here.